Anti-CEACAM5 (Labetuzumab)-CL2A-SN-38 ADC

TypeName:
Business Offer
Request Date:
2017/09/28
Country:
United States
Summary:
This ADC product is comprised of an anti-CEACAM5 monoclonal antibody conjugated via a CL2A linker to a SN-38. The SN-38 is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. The SN-38 is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cell, SN-38 binds to DNA, causes DNA damage. http://www.creative-biolabs.com/adc/target-ceacam5-21.htm
Description:
Advantages:
[RequestAdvantages]
Comments:
[RequestComments]
RequestId:
412
Name:
Creative Biolabs
Telphone:
Categories
No Man flag